KR20220012913A - 융합 복소환 유도체 - Google Patents

융합 복소환 유도체 Download PDF

Info

Publication number
KR20220012913A
KR20220012913A KR1020217042210A KR20217042210A KR20220012913A KR 20220012913 A KR20220012913 A KR 20220012913A KR 1020217042210 A KR1020217042210 A KR 1020217042210A KR 20217042210 A KR20217042210 A KR 20217042210A KR 20220012913 A KR20220012913 A KR 20220012913A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
hbv
membered monocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217042210A
Other languages
English (en)
Korean (ko)
Inventor
샌드린 셀린 그로세
린제이 그라함 데라트
코엔 반디크
피에르 장-마리 버나드 라보이션
세르게 마리아 알로이시우스 피에터스
바트 루돌프 로마니 케스텔린
윔 게스톤 베르스에런
얀 마틴 버크
모건 찰스 알 레콤트
캐롤라이나 마르티네즈 라멘카
팀 휴고 마리아 존커스
강 덩
이민 지앙
얀핑 슈
잔링 청
릴리 후
스콧 디. 쿠덕
Original Assignee
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220012913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 filed Critical 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Publication of KR20220012913A publication Critical patent/KR20220012913A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217042210A 2019-05-28 2020-05-27 융합 복소환 유도체 Withdrawn KR20220012913A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933.0 2019-05-28
US62/853,533 2019-05-28
EP19176933 2019-05-28
CNPCT/CN2020/085720 2020-04-20
CN2020085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (1)

Publication Number Publication Date
KR20220012913A true KR20220012913A (ko) 2022-02-04

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042210A Withdrawn KR20220012913A (ko) 2019-05-28 2020-05-27 융합 복소환 유도체

Country Status (19)

Country Link
EP (1) EP3976617B1 (https=)
JP (1) JP2022535734A (https=)
KR (1) KR20220012913A (https=)
CN (1) CN113906028A (https=)
AU (1) AU2020285718A1 (https=)
BR (1) BR112021022889A8 (https=)
CA (1) CA3138168A1 (https=)
CL (1) CL2021003155A1 (https=)
CO (1) CO2021016433A2 (https=)
CR (1) CR20210666A (https=)
DO (1) DOP2021000230A (https=)
IL (1) IL288322A (https=)
JO (1) JOP20210313A1 (https=)
MA (1) MA56043A (https=)
MX (1) MX2021014575A (https=)
PE (1) PE20220767A1 (https=)
PH (1) PH12021552974A1 (https=)
SG (1) SG11202113167QA (https=)
WO (1) WO2020243135A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744927A (zh) * 2020-12-02 2023-09-12 杨森科学爱尔兰无限公司 稠合杂环衍生物及其在治疗hbv感染中的用途
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
WO2022253255A1 (en) * 2021-06-02 2022-12-08 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives
CN117715909A (zh) 2021-06-02 2024-03-15 杨森科学爱尔兰无限公司 稠合杂环衍生物
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
RU2742305C2 (ru) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
AU2017290755B2 (en) * 2016-06-29 2021-07-01 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
JP6935434B2 (ja) * 2016-06-29 2021-09-15 ノヴィラ・セラピューティクス・インコーポレイテッド オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
SG11202111236UA (en) * 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Also Published As

Publication number Publication date
WO2020243135A1 (en) 2020-12-03
EP3976617B1 (en) 2025-04-23
BR112021022889A2 (pt) 2022-01-04
PE20220767A1 (es) 2022-05-16
CR20210666A (es) 2022-03-11
PH12021552974A1 (en) 2022-07-11
DOP2021000230A (es) 2022-05-31
EP3976617A1 (en) 2022-04-06
CA3138168A1 (en) 2020-12-03
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
CL2021003155A1 (es) 2022-07-22
JP2022535734A (ja) 2022-08-10
MA56043A (fr) 2022-04-06
MX2021014575A (es) 2022-05-24
CN113906028A (zh) 2022-01-07
JOP20210313A1 (ar) 2021-11-25
SG11202113167QA (en) 2021-12-30
AU2020285718A1 (en) 2022-02-03
IL288322A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
KR20220012913A (ko) 융합 복소환 유도체
EP4549438A1 (en) Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof
KR20180022818A (ko) 환화 술파모일아릴아미드 유도체 및 b형 간염 치료용 약제로서의 이의 용도
US11504382B2 (en) Tricyclic inhibitors of Hepatitis B virus
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
TW202313008A (zh) 稠合雜環衍生物(一)
US20220348592A1 (en) Fused heterocyclic derivatives
KR20220015420A (ko) 캡시드 조립 조절제로서의 디아제피논 유도체
KR20220012318A (ko) 융합 복소환 유도체
KR20220015426A (ko) 캡시드 조립 조절제로서의 융합 복소환 유도체
KR20220012321A (ko) 항바이러스제로서의 융합 헤테로고리 유도체
EA047929B1 (ru) Сочлененные гетероциклические производные
HK40066700A (zh) 稠合杂环衍生物
CN117715909A (zh) 稠合杂环衍生物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230523

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250225

WITB Written withdrawal of application